SEC Filing Summary: Capricor Therapeutics, Inc. (CAPR)
Business Context and Reporting Period
This Form 8-K, filed on August 12, 2021, serves as a current report for Capricor Therapeutics, Inc., a Delaware corporation. The filing announces the company's financial results for the quarter ended June 30, 2021. The report references a press release furnished as Exhibit 99.1 titled "Capricor Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update."
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The filing acts as a notification that these results have been issued in a separate press release (Exhibit 99.1), the content of which is not included in the source text provided.
Material Changes
The filing text does not provide data to compare current period performance against prior comparable periods. Specific details regarding material changes in financial condition or operations are contained within the referenced press release, which is not part of this text.
Guidance, Outlook, and Risks
The filing indicates that a corporate update was provided alongside the financial results in the attached press release. However, the text of this Form 8-K does not disclose specific guidance, management commentary, risks, contingencies, or unusual items. The information is explicitly stated as being furnished and not deemed filed for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Review Exhibit 99.1 (the press release) for actual Q2 2021 financial figures including revenue, net loss, and cash position.
- Verify the specific details of the "Corporate Update" mentioned in the filing title for clinical trial progress or strategic shifts.
- Confirm the company's cash runway and burn rate as these are not listed in the 8-K text.
- Check for any forward-looking statements or guidance provided in the full press release.